๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS ยท Real-Time Price ยท USD
1.370
-0.060 (-4.20%)
Nov 18, 2026, 4:00 PM EST - Market closed

Kalaris Therapeutics Earnings Call Transcripts

Fiscal Year 2025

  • EGM 2025

    The meeting focused on a reverse stock split proposal and a potential adjournment if more proxies were needed. Voting was conducted with a quorum present, and results will be published after certification. No questions were raised by stakeholders.

Fiscal Year 2024

  • M&A Announcement

    A merger will create a well-funded company focused on advancing TH103, a next-generation anti-VEGF therapy for retinal diseases. The deal is expected to close in Q1 2025, with a strong management team and sufficient cash to fund operations through 2026.

Fiscal Year 2023

Fiscal Year 2022